Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (300760.SZ)
| Previous Close | 272.20 |
| Open | 270.08 |
| Bid | 271.50 x 0 |
| Ask | 271.66 x 0 |
| Day's Range | 268.50 - 274.80 |
| 52 Week Range | 253.48 - 325.00 |
| Volume | |
| Avg. Volume | 3,822,722 |
| Market Cap | 330.027B |
| Beta (5Y Monthly) | 0.08 |
| PE Ratio (TTM) | 28.99 |
| EPS (TTM) | 9.36 |
| Earnings Date | Apr 28, 2024 - May 13, 2024 |
| Forward Dividend & Yield | 8.80 (3.24%) |
| Ex-Dividend Date | Nov 22, 2023 |
| 1y Target Est | 394.79 |
- Reuters
Chinese medical device firm Mindray plans $927 million deal to control APT Medical
BEIJING/HONG KONG (Reuters) -Chinese medical device company Shenzhen Mindray Bio-Medical Electronics said it planned a 6.65 billion yuan ($927 million) deal to gain control of APT Medical to expand in cardiovascular disease-related businesses. A wholly owned unit of Mindray will buy a 21.12% stake in APT Medical from current shareholders, including funds linked to venture investment firm Qiming Venture, for 6.65 billion yuan, Mindray said on Sunday. The Mindray unit will become the controlling shareholder of APT Medical after the transaction, according to a Mindray filing to the Shenzhen stock exchange.
South China Morning PostLuxury Hong Kong mansion on The Peak sells at 35% discount for US$107 million to company linked to Mindray founder
A mainland Chinese buyer snapped up an ultra-luxury house at The Peak in Hong Kong at a 35 per cent discount, reflecting the still lukewarm atmosphere in the city's luxury property market. The mansion, 25-26 A&B Lugard Road, sold for HK$838 million (US$107 million), or HK$71,703 per square foot, according to Godfrey Cheng, deputy senior director of the investment CEO office at Savills Hong Kong, the sole agent for the property. The sale is linked to Shenzhen entrepreneur Xu Hang, co-founder and
PR NewswireMindray Expands Its Cardiac Biomarker Portfolio with Cutting-Edge hs-cTnI and NT-proBNP Assays, Empowering Enhanced Cardiovascular Diseases Care
Mindray (SZSE: 300760), a global leader in medical devices and solutions, introduces high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The additions have enhanced Mindray's diverse portfolio of cardiac biomarkers for cardiovascular diseases (CVDs) diagnosis and management.
